China has moved a step closer to developing a home-grown mRNA vaccine against Covid-19, with the publication of early trial results for its prime candidate ARCoV.No serious adverse events were recorded in the phase 1 clinical trial data, published last week by The Lancet Microbe, but scientists said it was too early to judge its success.Large-scale trials of the vaccine – jointly developed by the Academy of Military Science, Walvax Biotechnology and Suzhou Abogen Biosciences – have been delayed…South China Morning Post
Related posts
Kazakhstan’s Leader Deepens U.S. Ties, Saying Trump Was ‘Sent by Heaven’
The skyline of Astana, the capital of Kazakhstan, is a physical reflection of the Central Asian...-
The Real A.I. Race Isn’t America vs. China
A globally recognizable tech executive, high-spirited from preparing for a public offering, offers imprudent remarks criticizing... -
Chinese Dissident Who Fled by Sea to South Korea Lands in Canada
About a month ago, the Chinese dissident Dong Guangping spent 36 hours at sea in an...
